Cancer Center Administration provides the overall administrative services that further the research and clinical missions of the P30 support grant. Administration has been extensively reorganized to address prior critiques, and to optimize its new position in the matrix Cancer Center formed following the December 2007 merger of the formerly independent CTRC with UTHSCSA. The new Associate Director of Administration has specific responsibilities commensurate with a senior leadership position within the Cancer Center. Administration provides a variety of critical functions in support of P30 operations, including: 1) providing oversight and coordination of P30-supported programs and shared resources, 2) serving as the direct liaison for, and supporting and coordinating the functions and meetings of key scientific and oversight committees, such as the Executive Committee, the Internal Advisory Committee, the External Advisory Board, program member meetings, and scientific retreats, 3) determining policy needs, and writing and implementing those policies for programs and shared resources, 4) providing financial accounting for all P30-related activities ncluding programs, shared resources, pilot programs, seminars, retreats and other activities, 5) coordinating and documenting use of P30-related laboratory, clinical and administrative space, 6) coordinating and overseeing P30-funded personnel, 7) coordinating communications among Cancer Center investigators and leadership, and UTHSCSA personnel, 8) serving as liaison with, and coordinator for funding sources including UTHSCSA and local and national agencies, 9) working closely with the Office of Research Administration to help ensure that clinical protocols and Material Transfer Agreements are executed, documented and maintained to appropriate standards and aligned well with UTHSCSA standards, and 10) coordinating informational communications between P30-supported scientific and clinical research arms and UTHSCSA, the region and the nation. Cancer Center Administration activities do not overiap with administrative functions supported elsewhere in the CTRC or in UTHSCSA, maximizing economies of scale.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA054174-19S5
Application #
8637187
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
19
Fiscal Year
2013
Total Cost
$15,949
Indirect Cost
$5,281
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Zanotto-Filho, Alfeu; Dashnamoorthy, Ravi; Loranc, Eva et al. (2016) Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human. PLoS One 11:e0153970
Newcomb, Lisa F; Thompson Jr, Ian M; Boyer, Hilary D et al. (2016) Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol 195:313-20
Ortiz, Carmen; Morales, Luisa; Sastre, Miguel et al. (2016) Cytotoxicity and Genotoxicity Assessment of Sandalwood Essential Oil in Human Breast Cell Lines MCF-7 and MCF-10A. Evid Based Complement Alternat Med 2016:3696232
Price, Douglas K; Chau, Cindy H; Till, Cathee et al. (2016) Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 122:2332-40
Zanotto-Filho, Alfeu; Masamsetti, V Pragathi; Loranc, Eva et al. (2016) Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Mol Cancer Ther 15:3000-3014
Sareddy, Gangadhara R; Li, Xiaonan; Liu, Jinyou et al. (2016) Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep 6:24185
Sweeney, Shannon R; Kavanaugh, Arthur; Lodi, Alessia et al. (2016) Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open 2:e000289
Schenk, Jeannette M; Till, Cathee; Hsing, Ann W et al. (2016) Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control 27:175-82
Toledo, Rodrigo A; Qin, Yuejuan; Cheng, Zi-Ming et al. (2016) Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res 22:2301-10
Wu, Anqi; Dong, Qiaoxiang; Gao, Hui et al. (2016) Characterization of mammary epithelial stem/progenitor cells and their changes with aging in common marmosets. Sci Rep 6:32190

Showing the most recent 10 out of 853 publications